首页|利妥昔单抗联合地塞米松治疗系统性红斑狼疮继发血小板减少患者的效果

利妥昔单抗联合地塞米松治疗系统性红斑狼疮继发血小板减少患者的效果

扫码查看
目的:观察利妥昔单抗联合地塞米松治疗系统性红斑狼疮(SLE)继发血小板减少患者的效果.方法:选取2020年9月至2022 年 9 月该院收治的 109 例SLE继发血小板减少患者进行前瞻性研究,按照随机数字表法将其分为观察组 55 例与对照组 54 例.对照组采用地塞米松磷酸钠注射液治疗,观察组在对照组基础上联合利妥昔单抗注射液治疗.比较两组临床疗效,治疗前后血小板计数(PLT)、血清炎性因子[B细胞活化因子(BAFF)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)]水平,以及不良反应发生率.结果:观察组治疗总有效率为96.36%(53/55),高于对照组的83.33%(45/54),差异有统计学意义(P<0.05);治疗后,观察组PLT水平高于对照组,血清IL-8、IL-10、BAFF水平低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:利妥昔单抗联合地塞米松治疗SLE继发血小板减少患者效果确切,能够提高患者PLT水平,降低血清IL-8、IL-10、BAFF水平,效果优于单用地塞米松治疗.
Effects of Rituximab combined with Dexamethasone in treatment of patients with thrombocytopenia secondary to systemic lupus erythematosus
Objective:To observe effects of Rituximab combined with Dexamethasone in treatment of patients with thrombocytopenia secondary to systemic lupus erythematosus(SLE).Methods:A prospective study was conducted on 109 patients with thrombocytopenia secondary to SLE admitted to the hospital from September 2020 to September 2022.According to the random number table method,they were divided into observation group(55 cases)and control group(54 cases).The control group was treated with Dexamethasone sodium phosphate injection,while the observation group was treated with Rituximab injection on the basis of that of the control group.The clinical efficacy,the platelet count(PLT),the serum inflammatory factors[B cell activating factor(BAFF),interleukin-8(IL-8),interleukin-10(IL-10)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 96.36%(53/55),which was higher than 83.33%(45/54)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the PLT level in the observation group was higher than that in the control group,the levels of serum IL-8,IL-10 and BAFF were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Rituximab combined with Dexamethasone is effective in the treatment of the patients with thrombocytopenia secondary to SLE,which can improve the PLT levels and reduce the levels of serum IL-8,IL-10 and BAFF.Moreover,it is superior to single Dexamethasone treatment.

RituximabSystemic lupus erythematosusThrombocytopeniaInflammatory factorDexamethasone

刘文辉、于洋、李俊红

展开 >

正阳县人民医院肿瘤血液科,河南 驻马店 463600

利妥昔单抗 系统性红斑狼疮 血小板减少 炎性因子 地塞米松

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(11)
  • 11